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Abstract
Background: Previous studies suggest that psychotropic drug changes may signal an acute period of time
whereby a person is highly vulnerable to fall. It is unknown whether certain classes of psychotropic agents are less
safe with respect to the acute risk of falls. Our purpose was to compare fall rates in the 7 days following a change
of an antidepressant, antipsychotic, or benzodiazepine. We also identified specific times when residents are at high
risk for falls with respect to a psychotropic drug change.
Methods: Residents in our one-year study included 851 long term care residents from two nursing home facilities
in Boston, MA, U.S.A. (May 2010 - May 2011). Drug changes (i.e., new prescriptions or increased dose of a previously
used drug) were ascertained using the computerized provider order entry system, whereas falls were ascertained by
incident reports. Negative binomial regression was used to compare the rate of falls following a drug change
between medication classes. Further, we calculated the rate of falls for each of the 7 days before and 7 days after a
psychotropic drug change.
Results: Forty-eight percent of residents were prescribed a new prescription or increased dose of a psychotropic
drug during the study. The rate of falls was similar in the 7 days following a change to a SSRI versus non-SSRI
antidepressant (11.9 versus 14.4 falls/1,000 person years; p= 0.58), a typical versus an atypical antipsychotic (25.4
versus 17.1 falls/1,000 person years; p= 0.10), or a short versus long acting benzodiazepine (15.2 versus 13.9 falls/
1,000 person years; p =0.23). Fall risk was highest on day 4 before the drug change (19.0 falls/1,000 person days),
on the day of the drug change through 2 days after the drug change (17.6-20.3 falls/1,000 person days), and
5-6 days after the drug change (17.6-19.0 falls/1,000 person days).
Conclusions: In the nursing home, risk of falls was similar following a psychotropic drug change of any class. We
observed higher fall risk in the days before, but mostly after the drug change. We recommend that nursing home
residents be closely monitored following a psychotropic drug change in an effort to reduce falls.
Keywords: Falls, Nursing home, Psychotropic drug change
Background
Falls in the nursing home are a serious health concern.
As many as 3 out of 4 nursing home residents fall each
year [1]. Nearly 10% of these falls result in fracture or
serious injury [2]. The average cost per fall in the nurs-
ing home is $1,892 [3]. Even falls that do not result in
injury can diminish self-confidence and cause loss of
function [4]. Efforts to decrease falls in nursing home
residents are needed to protect lives and reduce costs.
Psychotropic medications are associated with a 30-70%
increased risk of falls [5,6]. Despite awareness that these
medications may predispose an elderly person to fall,
psychotropic drugs remain widely used (often for life) in
the nursing home setting. It is important then, to iden-
tify specific time points or triggering events for falls
among psychotropic drug users in order to target fall
prevention efforts effectively.
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signal an acute period of time whereby a nursing home
resident is highly vulnerable to fall. For example, two
small studies of nursing home residents found a 3–5 fold
increased risk of falls within 3 days of a new prescription
for a drug that affects the central nervous system [7,8].
It is unknown whether certain classes of psychotropic
agents are less safe with respect to the acute risk of falls.
Our objective was to compare the rate of falls in the
7 days following an antidepressant, antipsychotic, or
benzodiazepine prescription drug change in a large, pro-
spective cohort of long term care residents. We further
described the rate of falls in the 7 days before and the 7 -
days after a drug change, in order to identify specific
times when psychotropic medication users are particu-
larly vulnerable to fall.
Methods
Participants
Residents in our year-long study included all long-stay
residents of two nursing home facilities (Boston, MA,
U.S.A.) between May 29, 2010 - May 28, 2011. Residents
admitted to the short term rehabilitation units were not
included. This population represents a dynamic cohort,
as new residents are admitted and others are rehabili-
tated or pass away. This study was approved by the
Hebrew SeniorLife IRB (Protocol #08-015). Informed
consent was not required.
Medication changes
Information on psychotropic drug changes was obtained
using a computerized provider order entry system,
MEDITECH™. A change was defined as either a new
prescription or an increased dose of a currently pre-
scribed psychotropic medication. A new prescription was
defined as any prescription that was not used in the past
90 days on an as needed or scheduled basis. Changing
drugs within a class of medications (i.e. replacing parox-
etine with sertraline) was categorized as a new prescrip-
tion. A dose increase was defined as an increase in the
cumulative daily dose of a currently used medication or
a medication that was prescribed in the past 90 days. A
prescription ordered on the day of admission, started
and stopped on the same day, and prescription renewals
were not included as a drug change.
We used the American Hospital Formulary Services
(AHFS Pharmacologic-Therapeutic Classification System)
to classify medications as antidepressants (tricyclic, select-
ive serotonin reuptake inhibitor (SSRI), miscelaneous), an-
tipsychotics (typical and atypical), or benzodiazepines
(short and long acting) [9]. We combined tricyclic and
miscellaneous antidepressants in the category ‘non-SSRI
antidepressants’ because there were too few tricyclic
antidepressant changes (n=9) to consider separately.
Examples of non-SSRI antidepressants include nortripty-
line, trazodone, mirtazapine, bupropion, and venlafaxine.
Other variables
Information on cognitive status, pain, depression, and
clinical characteristics that could be associated with the re-
ceipt of a psychotropic medication was ascertained using
the Minimum Data Set (MDS) assessment performed
closest to study entry (mean 35 days after study entry;
range 0 days- 248 days after study entry). The MDS is a
federally mandated assessment used to standardize detec-
tion of quality indicators in long term care facilities [10].
Cognitive impairment was classified as none or mild
(0–1), moderate (2–4), or severe (5–6) using a validated
Cognitive Performance Scale [11]. Pain was assessed using
the Visual Analogue Scale and categorized as none (0),
mild (1), or moderate to severe (2–3) [12]. Depression was
assessed by a validated MDS Depression Rating Scale [13],
and categorized as none (score 0), mild to moderate (score
1–2), or severe (score 3+). Clinical characteristics that
could be associated with the receipt of a psychotropic
medication including sadness, wandering, verbal or phys-
ical abuse, socially inappropriate behavior, and resistance
to care were described as present or absent in the 7 days
prior to completion of the MDS.
Falls
Falls were ascertained prospectively through the facil-
ities’ computerized incident reports. Nursing staff are
trained annually on proper incident reporting. A fall was
defined as accidentally coming to rest on the ground or
lower surface, such as a chair.
Statistical analysis
We compared characteristics between residents that
never used psychotropic drugs, residents with chronic
use of psychotropic drugs without a medication change,
and residents with a psychotropic drug change during
follow-up using ANOVA for continuous variables, and
the Chi-squared test for categorical variables.
To calculate the rate of falls following a psychotropic
drug change, we divided the total number of falls that
occurred in the 7 days after a psychotropic drug change
by the person days following the drug change. We used
negative binomial regression adjusting for individual
effects to compare the rates of falls following a drug
change between classes of psychotropic medications
[14]. Fully adjusted models considered age, sex, cognitive
impairment, functional status, and pain. We planned to
include history of falls in our models, but this resulted
in unstable estimates. We believe this is because the ma-
jority of residents with a recurrent fall during the 7 days
following a drug change were the same residents with a
history of falls. Our models already included a random
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fect and the highly correlated exposure of history of falls
was not possible.
We described the rate of falls for each of the 7 days
before and 7 days after a psychotropic drug change (no
formal statistical test). We excluded drug changes that
occurred≤ 14 days apart in the same participant (n=
283), in order to standardize time with respect to the
date of the drug change. We do not present daily fall
rates by medication class separately because the number
of falls on an individual day was small when drugs were
separated, and similar trends were observed for each
class of medications.
Results
During the one year study, 851 nursing home residents
contributed a mean of 262 person-days of follow-up.
Mean age of residents was 87 years and 75% were female.
Forty-eight percent were prescribed a new psychotropic
medication or an increased dose of a psychotropic medi-
cation. There was little difference in age, sex, and cogni-
tive status of residents with a psychotropic drug change as
compared to residents who used psychotropic medications
without change or residents who never used psychotropic
medications (Table 1). Residents with a psychotropic drug
change were more likely to have moderate to severe pain
as compared with residents who used psychotropic drugs
without change (Table 1; 18.0% versus 11.9%, p<0.001).
The proportion of residents with≥2 falls during follow-up
was greater among residents with a psychotropic drug
change as compared to psychotropic users without change
(41.0% versus 22.5%, p<0.001).
During follow-up there were 407 new prescriptions for
a psychotropic medication and 616 dose increases of a
psychotropic medication (Table 2). The total number of
new prescriptions was highest for short acting benzodi-
azepines (n =160) and lowest for typical antipsychotics
and long acting benzodiazepines (n= 18 each). Dose in-
creases occurred most frequently with atypical antipsy-
chotics (n =194) and least frequently among typical
antipsychotics (n =27) and long acting benzodiazepines
(n =23). The most common clinical characteristics
reported among residents that received an antidepres-
sant change were sadness (60%) and resistance to care
(25%). Among residents with an antipsychotic change,
sadness (70%), socially inappropriate behaviors (32%), re-
sistance to care (36%), and verbal abuse (28%) were
commonly reported, whereas residents with a benzodi-
azepine change were often characterized as sad (59%) or
resistive to care (28%).
Among 851 residents, 420 residents experienced a
total of 1,205 falls during the study period (5.4 falls/
Table 1 Characteristics of 851 long term care residents as categorized by whether a psychotropic drug change
occurred during follow-up (%, unless indicated)
Psychotropic drug
change
Psychotropic user
without a drug
No psychotropic
medication use
P-value
(n=405) change (n= 289) (n=157)
Mean age (years, ± S.D.) 87.4±8.8 86.9± 8.5 87.1±10.2 0.76
Female 75.1 73.0 75.8 0.76
Cognition
Normal or mild impairment 20.1 20.6 29.0
Moderate impairment 58.6 52.4 44.7
Severe impairment 21.3 27.1 26.3 0.03
Pain
None 55.6 66.4 74.5
Mild 26.4 22.0 13.1
Moderate to severe 18.0 11.6 12.4 <0.001
Depression
None 41.4 60.5 74.2
Mild to moderate 26.3 20.7 15.9
Severe 32.3 18.8 9.9 <0.001
Fallers during 1 year follow-up
1 fall 23.5 18.7 13.4
≥ 2 falls 41.0 22.5 12.1 <0.001
Rate of falls during 1 year follow-up (per 1,000 person-days) 7.6 4.1 2.0 <0.001
Mean follow-up (days, ± S.D.) 268± 121 258±136 255±132 0.47
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http://www.biomedcentral.com/1471-2318/13/19Table 2 Number of psychotropic drug changes and rate of falls in the 7 days following the psychotropic drug change among 851 long term care residents
over one year of follow-up
Psychotropic medication New prescription Dose increase Combined medication change
# of new
prescriptions
# falls in the
7 days after the
med change
Rate of falls in
the 7 days after
the med change*
# of dose
increases
# Falls in the
7 days after the
med change
Rate of falls in
the 7 days after
the med change*
# of drug changes # Falls in the
7 days after
the drug change
Rate of falls in
the 7 days after
the drug change*
Antidepressants 155 19 17.5 221 17 11.0 376 36 13.7
SSRIs 46 4 12.4 62 5 11.5 108 9 11.9
Non-SSRIs 109 15 19.7 159 12 10.8 268 27 14.4
Antipsychotics 74 7 13.5 221 31 20.0 295 38 18.4
Typical 18 2 15.9 27 6 31.7 45 8 25.4
Atypical 56 5 12.8 194 25 18.4 250 30 17.1
Benzodiazepines 178 18 14.4 174 19 15.6 352 37 15.0
Long-Acting 18 2 15.9 23 2 12.4 41 4 13.9
Short-Acting 160 16 14.3 151 17 16.1 311 33 15.2
* per 1,000 person days.
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91,000 person days). The rate of falls was similar in the
7 days following a psychotropic drug change of any kind
(Table 2; p ≥ 0.1 for all comparisons). Specifically, there
was no difference in the rate of falls following a change
to a SSRI versus non-SSRI antidepressant (11.9 versus
14.4 falls/1,000 person years; p =0.58), a typical versus
an atypical antipsychotic (25.4 versus 17.1 falls/1,000
person years; p= 0.10), or a short versus long acting
benzodiazepine (15.2 versus 13.9 falls/1,000 person
years; p= 0.23).
In the 7 days before and 7 days after a psychotropic
drug change, 70 residents fell once and 24 residents fell
multiple times (range 2–4 falls). Of the recurrent fallers,
13 fell in both the 7 days before and 7 days after the
drug change. Three residents fell multiple times in the
week before the drug change, whereas 7 residents fell
multiple times in the week after the drug change. One
resident fell twice on the day of the drug change.
The rate of falls was elevated in the days before and
after a psychotropic drug change as compared with the
rate of falls among psychotropic drug users that did not
experience a medication change during follow-up, or
compared with the annual rate of falls among psycho-
tropic drug users that experienced a drug change
(Figure 1). Specifically, risk of falls was elevated on day 4
before the drug change (19.0 falls/1,000 person days).
Risk was also elevated on the day of the drug change
through 2 days after the drug change (17.6-20.3 falls/
1,000 person days), and days 5 to 6 after the drug change
(19.0 and 17.6 falls/1,000 person days). On day 7 before
the drug change and day 7 after the drug change, rates
of falls were somewhat lower (2.7 and 8.2/1000 person
days, respectively). In comparison, the annual rate of
falls among psychotropic users with a drug change over
the one year study was 7.6 /1,000 person days, and the
annual rate of falls among psychotropic users without a
drug change was 4.1/1,000 person days.
Discussion
Our study suggests that there may be no acute protec-
tion afforded with respect to falls risk by selecting a
newer versus older class of antidepressants or antipsy-
chotics or a short acting versus long acting benzodiazep-
ine. Previous studies have determined that the long term
risk of falls and injurious falls was no different among
users of tricyclic versus SSRI antidepressants [15], or
among users of typical versus atypical antipsychotics
[16]. Similarly, use of both short and long acting benzo-
diazepines has been associated with an equally elevated
longitudinal risk of falls in community dwellers [17,18].
Thus, there is no evidence to support selection of psy-
chotropic agents based on risk of falls.
Our finding that there was a high risk of falls in the
days immediately following a psychotropic drug change
is consistent with other studies. Using a self-controlled,
case-crossover approach, Sorock and Neutel both found
that the fall risk in nursing home residents was max-
imally increased within 2–3 days of a change in a
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Figure 1 Distribution of the rate of falls in nursing home residents with respect to a psychotropic drug change. Negative values indicate
days prior to the drug change, whereas positive values indicate days after the drug change. The number of falls is presented above each bar
graph. Fall risk was greatest: 1) 4 days prior to the drug change, 2) on the day of the drug change through 2 days after the drug change, 3)
5–6 days after the drug change. For comparison, we present A) the annual rate of falls among psychotropic users with a drug change during
one-year follow-up, B) the annual rate of falls among psychotropic users without a drug change during one-year follow-up.
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Previous work by our group showed that changes in spe-
cifically non-SSRI antidepressant prescriptions increased
the risk of falls within 2 days, with a subsequent de-
creased risk of falls over the next 5 days [19]. Zint et al.
concluded that in community dwellers, hip fracture risk
associated with benzodiazepines was highest in users
within 14 days of initiation [20].
Nonetheless, it is possible that the high rates of falls
we observed are due to random variation in falls rates
or because residents with psychotropic drug changes
have more risk factors for falls, such as orthostatic
hypotension, muscle weakness, or prior falls, predispos-
ing them to fall. We did not have information on ortho-
static hypotension or muscle weakness in order to adjust
for these characteristics in our models. Although we had
information on history of falls, this characteristic was
not used in the final models due to statistical instability
when we included both history of falls and an individual
effect in the same model. When we included in our
model a history of falls rather than a random patient ef-
fect, the associations between psychotropic drug changes
and rate of falls did not change. We do not believe that
any of these characteristics would fully account for the
markedly elevated risk of falls we observed following a
drug change. The rate of falls in the 7 days following
an antidepressant, antipsychotic, or benzodiazepine drug
change ranged from 13.7 to 18.4/1,000 person days. This
is much greater than the annual rate of falls among resi-
dents that used psychotropic medications without change
(4.1/1,000 person days) or the annual rate of falls among
residents with a psychotropic drug change (7.1/1,000
person days).
While we observed that the rate of falls was highest
one day following a psychotropic drug change, rates of
falls were also elevated 3 to 4 days preceding the drug
change. This suggests that the underlying medical condi-
tion for which the medication was prescribed also con-
tributed to the increased risk of falls. In the nursing
home, psychotropic medication changes are often made
in an effort to manage psychiatric symptoms in persons
with dementia, such as wandering, combativeness, and
insomnia. Behavioral symptoms may begin days before
pharmacologic treatment is selected resulting in an in-
creased risk of falls before drug initiation.
Separating the effects of a drug from the effects of the
underlying medical condition can be challenging. In our
study, exposure to a psychotropic drug change was
highly correlated with dementia with psychiatric symp-
toms. Attempts to adjust for psychiatric symptoms using
a traditional model or propensity scores would have
been of limited utility given the very high correlation be-
tween drug exposure and the psychiatric conditions [21].
Instead, we used a comparator medication strategy to
determine if falls risk differed between classes of medica-
tions that are used to treat similar medical conditions.
An alternative approach would have been a stratified or
restrictive analysis, grouping residents with similar acute
symptoms together [21]. One could test the hypothesis
that it is the medical illness rather than the drug causing
the observed risk by repeating the analysis with an alter-
native outcome that is known to have no association
with the drug of interest [22]. We did not have an ad-
equate sample size or precise information on other acute
illnesses in order to use these strategies. Our study sug-
gests that the rate of falls may be elevated in the days
surrounding a psychotropic drug change. While it may
be impractical to distinguish between the effects of the
drug and the underlying medical condition, the implica-
tions of our findings remain: attention should be given
to residents experiencing a psychotropic drug change in
an effort to prevent falls.
Strengths of this study include a large, prospective co-
hort of long term care residents with complete informa-
tion on medications and falls. Additionally our study
addresses an important clinical question of whether cer-
tain psychotropic agents are less safe with respect to the
acute risk of falls.
This study also has several potential limitations. First,
we had small numbers of falls on individual days with
respect to the drug change. While this may result in
some variability of fall rates between days, overall trends
were observed. Second, we were unable to consider the
sizes of all new prescriptions and increased doses separ-
ately, and we did not consider concomitant medication
changes given the limited number of falls in our study.
For example, in our one-year study, 376 antidepressant
changes occurred with only 36 falls within 7 days of the
drug changes. Only a small fraction of antidepressant
changes were associated with a concomitant benzodi-
azepine or antipsychotic drug change. Hanlon et al.
found that risk of falling increases with the number and
dosage of psychotropic medications [23], and it is pos-
sible that acute fall rates were underestimated in our
study among residents who received a higher dose or
multiple psychotropic medications. We recommend that
future studies with a longer period of follow-up consider
the effects of dose and concomitant drug changes on the
risk of falls.
Third, information was not available on decreases or
discontinuations in dosage so that we were not able to
examine the effect of psychotropic drug reductions on
the acute risk of falls. Withdrawal syndromes are pos-
sible with discontinuation of psychotropic medications,
and could potentially result in an acute increased risk of
falls. It is unlikely that decreases are a common cause of
falls as previous studies suggest withdrawal of psycho-
tropic medications reduces the risk of falls [24,25].
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tropic agents are not mutually exclusive with the possibil-
ity of an acute risk of falling in the days after a decrease
or discontinuation. Fourth, we did not have resident spe-
cific information on days spent outside the facility. We ex-
pect this number would be low, and accounting for days
outside the facility would likely increase the rates of falls
only slightly.
Finally, our study was conducted in two facilities oper-
ated by a single organization. In comparison with other
facilities in the U.S., the proportion of residents pre-
scribed an antidepressant or benzodiazepine was greater
than the national average, while the proportion of resi-
dents prescribed an antipsychotic was similar to the na-
tional average [26,27]. In other countries, the prevalence
of psychotropic drug use may be lower. The absolute ef-
fect of psychotropic drug changes on falls may be more
or less significant depending on the frequency of use.
Conclusions
We found the risk of falls in the 7 days following a psy-
chotropic drug change is similar for antidepressants, anti-
psychotics, or benzodiazepines. Changes in psychotropic
drugs are associated with an elevated risk of falls 4 days
before the drug change, likely due to underlying psychi-
atric symptoms. Nursing home residents are also at an in-
creased risk of falling in the days immediately following a
psychotropic drug change, likely due to the effects of the
drug itself and the medical illness. Increased staff aware-
ness might help to reduce falls during this time. We sug-
gest that nursing home residents should be monitored
closely in the days following a psychotropic drug change
in an effort to reduce falls.
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